755 related articles for article (PubMed ID: 33986723)
21. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
22. MiR-324-5p/PTPRD/CEBPD axis promotes papillary thyroid carcinoma progression via microenvironment alteration.
Yang Y; Xia S; Zhang L; Wang W; Chen L; Zhan W
Cancer Biol Ther; 2020 Jun; 21(6):522-532. PubMed ID: 32151175
[TBL] [Abstract][Full Text] [Related]
23. IL-17A increases MHC class I expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis.
Han LT; Hu JQ; Ma B; Wen D; Zhang TT; Lu ZW; Wei WJ; Wang YL; Wang Y; Liao T; Ji QH
Diagn Pathol; 2019 Jun; 14(1):52. PubMed ID: 31159823
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of neutrophils-to-lymphocytes ratio (NLR), PD-L1 expression, and tumor immune microenvironment in laryngeal cancer.
Franz L; Alessandrini L; Fasanaro E; Gaudioso P; Carli A; Nicolai P; Marioni G
Ann Diagn Pathol; 2021 Feb; 50():151657. PubMed ID: 33189034
[TBL] [Abstract][Full Text] [Related]
25. Immune Profiling of Advanced Thyroid Cancers Using Fluorescent Multiplex Immunohistochemistry.
Ahn J; Jin M; Song E; Ryu YM; Song DE; Kim SY; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim WG
Thyroid; 2021 Jan; 31(1):61-67. PubMed ID: 32611231
[No Abstract] [Full Text] [Related]
26. Immune Escape Mechanism is Impaired in the Microenvironment of Thyroid Lymph Node Metastasis.
Cunha LL; Nonogaki S; Soares FA; Vassallo J; Ward LS
Endocr Pathol; 2017 Dec; 28(4):369-372. PubMed ID: 28730569
[TBL] [Abstract][Full Text] [Related]
27. Immune cell infiltrate-associated dysregulation of DNA repair machinery may predispose to papillary thyroid carcinogenesis.
Nicolson NG; Brown TC; Korah R; Carling T
Surgery; 2020 Jan; 167(1):66-72. PubMed ID: 31439400
[TBL] [Abstract][Full Text] [Related]
28. Single-Cell Transcriptome Analysis Reveals Inter-Tumor Heterogeneity in Bilateral Papillary Thyroid Carcinoma.
Wang T; Shi J; Li L; Zhou X; Zhang H; Zhang X; Wang Y; Liu L; Sheng L
Front Immunol; 2022; 13():840811. PubMed ID: 35515000
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the
Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Hennart B; Allorge D; van Geel N; Van Gele M; Brochez L
Oncoimmunology; 2015 Mar; 4(3):e982382. PubMed ID: 25949897
[TBL] [Abstract][Full Text] [Related]
30. Targeting and exploitation of tumor-associated neutrophils to enhance immunotherapy and drug delivery for cancer treatment.
Zhang Y; Guoqiang L; Sun M; Lu X
Cancer Biol Med; 2020 Feb; 17(1):32-43. PubMed ID: 32296575
[TBL] [Abstract][Full Text] [Related]
31. Recent advances in understanding immune phenotypes of thyroid carcinomas: prognostication and emerging therapies.
Liotti F; Prevete N; Vecchio G; Melillo RM
F1000Res; 2019; 8():. PubMed ID: 30854191
[TBL] [Abstract][Full Text] [Related]
32. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
33. Current and future immunotherapies for thyroid cancer.
Antonelli A; Ferrari SM; Fallahi P
Expert Rev Anticancer Ther; 2018 Feb; 18(2):149-159. PubMed ID: 29241377
[TBL] [Abstract][Full Text] [Related]
34. Immune profiling identifies CD8
Chen Z; Guo ML; Li YY; Yan K; Li L; Shen F; Guan H; Liu QZ; Xu B; Lian ZX
Front Immunol; 2022; 13():894919. PubMed ID: 36420264
[TBL] [Abstract][Full Text] [Related]
35. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
36. Immune responses in the thyroid cancer microenvironment: making immunotherapy a possible mission.
Mould RC; van Vloten JP; AuYeung AWK; Karimi K; Bridle BW
Endocr Relat Cancer; 2017 Dec; 24(12):T311-T329. PubMed ID: 28912377
[TBL] [Abstract][Full Text] [Related]
37. Tumor microenvironment in thyroid cancer: Immune cells, patterns, and novel treatments.
Febrero B; Ruiz-Manzanera JJ; Ros-Madrid I; Hernández AM; Orenes-Piñero E; Rodríguez JM
Head Neck; 2024 Jun; 46(6):1486-1499. PubMed ID: 38380767
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
39. Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model.
Nascimento C; Ferreira F
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188587. PubMed ID: 34237352
[TBL] [Abstract][Full Text] [Related]
40. Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function.
La Fleur L; Botling J; He F; Pelicano C; Zhou C; He C; Palano G; Mezheyeuski A; Micke P; Ravetch JV; Karlsson MCI; Sarhan D
Cancer Res; 2021 Feb; 81(4):956-967. PubMed ID: 33293426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
